login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Revolutionary impact of flow diversion/modification on treatment of certain aneuryms


Friday, 30 Sep 2011 11:45
Saruhan Çekirge
Saruhan Çekirge


Saruhan Çekirge, professor, Hacettepe University Hospitals, Ankara,Turkey, told delegates at the European Society of Minimally Invasive Neurological Therapy congress (ESMINT) held in Nice, France, that the impact of flow diversion/modification on the endovascular treatment of aneurysms with an important branch originating from the aneurysm sac was a “revolutionary change”.


He also told delegates: “In endovascular aneurysm treatment with flow diverters, there has been a strong consideration regarding the side branch or perforator patency. There have been anecdotal cases reporting perforating injury in the literature. In our experience, covering a segment, with branches coming off, with flow diverters especially with a single device, does not result in clinical consequence. If there is a flow demand, the vessel stays open; if not, it may close or become hypoplastic. This is most interesting that if there is a flow demand it stays open, so there is very intelligent behaviour.”


“Control studies have shown that flow diversion/modification treatment provides revolutionary changes not only for aneurysms which are large/giant and fusiform, for very small, difficult or impossible- to-coil ones and also for aneurysms with an important vessel coming off the sac which used to be the major limitation for endovascular treatment,” he added.


In the Hacettepe FD Pipeline/Silk series of 269 aneurysms in 211 patients, there was a subgroup of 46 aneurysms with a vessel originating from the aneurysm sac. In this group of 46 aneurysms with a vessel originating from the aneurysm sac, 23 aneurysms were in the internal carotid-anterior choroidal artery, 11 in the posterior communicating, four in the posterior inferior coronary artery, two in the distal anterior cerebral artery, one in the distal posterior communicating artery and five in the middle cerebral artery with important side branches originating .

 

“In 33 of these 46 aneurysms, six months and/or one year follow-up DSA was obtained. Investigators found that out of these 33 aneurysms which were controlled, all but one vessel (posterior communicating artery) originating from the aneurysm sac stayed open. Twenty aneurysms closed with perfect reconstruction and 13 aneurysm sacs were remodeled back. No clinical consequences developed except for one patient with an internal carotid-anterior choroidal aneurysm who stopped using clopidogrel after one week and had a transient ischaemic attack with a very small diffusion MR lesion in the territory. This patient returned to normal in 24 hours and a six-month control DSA revealed complete aneurysm occlusion with patency of the artery,” said Çekirge.




Add New Comment

Most popular


ROADSTER trial studying new path to carotid revascularisation completes patient enrolment
Friday, 18 Jul 2014
The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally ... ROADSTER trial studying new path to carotid revascularisation completes patient enrolment

Friday, 11 Jul 2014
This new patent grants six claims surrounding the use of the company’s Barrel vascular reconstruction device technology platform. New US patent for Barrel vascular reconstruction device

InspireMD announces completion of CGuard CARENET trial
Wednesday, 09 Jul 2014
Enrolment is complete in the CARENET trial, which is assessing the peri-procedural safety and efficacy of CGuard systems in the treatment of carotid lesions. InspireMD announces completion of CGuard CARENET trial

Features


Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Early brain stimulation may help stroke survivors recover language function
Monday, 21 Jul 2014
Dieter Heiss, who presented on early brain stimulation for stroke patients at the 8th World Congress on Controversies in Neurology (CONy), 8–11 May, Berlin, Germany, writes for NeuroNews on how this ... Early brain stimulation may help stroke survivors recover language function

Profiles


Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

William T Couldwell
Thursday, 24 Apr 2014
William T Couldwell is professor of neurosurgery in the Department of Neurological Surgery, U... William T Couldwell

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions